Stock Events

Novavax 

M$93
0
+M$3+3.33% Monday 20:49

Statistics

Day High
98
Day Low
92
52W High
183.91
52W Low
65.1
Volume
4,980
Avg. Volume
485
Mkt Cap
19.69B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

28FebExpected
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Next
-6.53
-2.52
1.49
5.5
Expected EPS
-0.38
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NVAX.MX. It's not an investment recommendation.

About

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Show more...
CEO
Mr. Stanley Charles Erck
Employees
1541
Country
United States
ISIN
US6700024010
WKN
000A2PKMZ

Listings